As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that ...

DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

AstraZeneca and its partner Daiichi Sankyo have obtained the Food and Drug Administration’s green light for Datroway to treat an advanced form of non-small cell lung cancer in adults who had ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the ...

Supported by Daiichi Sankyo Company, Limited, and Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ; and by Daiichi Sankyo, Inc (U31402-A-U102).

The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR ...

With expansion plans underway, Disney said that the Monsters, Inc. Mike & Sulley to the Rescue! ride at Disney's California Adventure will close in early 2026.

On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2.